DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07215559

RecruitingPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

Assets

Eloralintide / Macupatide

Listed sites

38

Recruiting sites

38

Enrollment

200

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•HbA1c 7.5-10.5%

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07215559
Org study ID27721
Secondary IDJ2V-MC-GZLFEli Lilly and Company

Timeline

Milestones

Study first posted2025-10-10actual
Study start2025-10-16actual
Last update posted2026-05-14actual
Primary completion2027-03estimated (month precision)
Study completion2027-05estimated (month precision)

Assets

Investigational agents

EloralintideMacupatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have type 2 diabetes
•Have an HbA1c ≥7.5% to ≤10.5% at screening
•Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
–Diet and exercise
–Stable dose of metformin
–Sodium-glucose cotransporter-2 (SGLT2) inhibitor
•Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening
•Have a BMI of 27 or greater at screening

Exclusion criteria

•Have any form of diabetes other than type 2 diabetes
•Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
•Have any of the following cardiovascular conditions within 3 months prior to screening:
–acute myocardial infarction
–cerebrovascular accident (stroke)
–unstable angina, or
–hospitalization due to congestive heart failure
•Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
–basal or squamous cell skin cancer
–in situ carcinomas of the cervix, or
–in situ prostate cancer
•Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
–amylin RA
–dual amylin and calcitonin RA
–glucagon-like peptide-1 receptor (GLP-1) RA
–glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
–GLP-1/glucagon (GCG) RAs, or
–GIP/GLP-1/GCG RAs
•Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
•Have used insulin for diabetic control within the prior year (short term use in certain situations allowed

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Glycemic / diabetes
2

Weight & body composition

2 endpoints
Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 32

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 32

BMI, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 32

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change from Baseline in Fasting Glucose

Time frame:Baseline, Week 32

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.